

Accepted Manuscript

The history and use of the progesterone receptor modulator, ulipristal acetate, for heavy menstrual bleeding with uterine fibroids

Philippe Bouchard, Nathalie Chabbert Buffet

PII: S1521-6934(16)30143-2

DOI: [10.1016/j.bpobgyn.2016.12.002](https://doi.org/10.1016/j.bpobgyn.2016.12.002)

Reference: YBEOG 1677


To appear in: *Best Practice & Research Clinical Obstetrics & Gynaecology*

Received Date: 11 August 2016

Accepted Date: 7 December 2016

Please cite this article as: Bouchard P, Chabbert Buffet N, The history and use of the progesterone receptor modulator, ulipristal acetate, for heavy menstrual bleeding with uterine fibroids, *Best Practice & Research Clinical Obstetrics & Gynaecology* (2017), doi: 10.1016/j.bpobgyn.2016.12.002.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



The history and use of the progesterone receptor modulator, ulipristal acetate, for heavy menstrual bleeding with uterine fibroids.

Philippe Bouchard,* Nathalie Chabbert Buffet**

*University Pierre et Marie Curie, Hospital saint Antoine 75012 Paris, and Department of Ob Gyn, Hospital Foch 92150 Suresnes, France.

** Department of Ob Gyn Hospital Tenon 75020 Paris France.

In collaboration with J Donnez, BCJM Fauser, ARW Williams, D Barlow, and E Loumaye (who have played a major role in the clinical trials of ulipristal).

Corresponding author:

Philippe Bouchard

University Pierre et Marie Curie, Hospital saint Antoine 75012 Paris, and Department of Ob Gyn, Hospital Foch 92150 Suresnes, France.

E-mail: phbouchard1@me.com

* P.B. is a member of PregLem's Scientific Advisory Board. During the most recent 5 year period Prof. Bouchard has received fees and grant support from the following entities (in alphabetic order); Actavis/Watson/Uteron, Euroscreen, Ferring, HRA Pharma, Pierre Fabre, Merck Serono, Pantharei Bioscience, The Population Council, PregLem/Gedeon Richter, Shin Poon Pharma.

Download English Version:

<https://daneshyari.com/en/article/5691434>

Download Persian Version:

<https://daneshyari.com/article/5691434>

[Daneshyari.com](https://daneshyari.com)